Fushimi et al. conducted a phase II trial on combined androgen blockade with leuprorelin and bicalutamide in patients with recurrent or metastatic salivary gland cancer, especially SDC, and they discovered that this regime has equivalent efficacy and less toxicity for AR-positive recurrent/metastatic or unresectable locally advanced cases compared to conventional chemotherapy, with an overall response rate and disease control rate of 42% and 86%, respectively, and a median overall survival of 30.5 months [13]. Here, AR is linked to salivary gland cancer.